Gettinger S, et al. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. Abstract OA14.04. WCLC 7-10 sept. 2019, Barcelona, Spanje.
Betere therapie voor cervixcarcinoom door afremmen DNA-reparatie tumorcellen
apr 2017 | Gynaecologische oncologie